Compositions and methods for reducing body fat

• US 9,144,574 B2
• Filed: 10/02/2014
• Issued: 09/29/2015
• Est. Priority Date: 03/23/2006
• Status: Active Grant

• Current Assignee: Topokine Therapeutics, Inc. (Abbvie Incorporated)
• Original Assignee: Topokine Therapeutics, Inc. (Abbvie Incorporated)
• Inventors: Grosskreutz, Cynthia L., Pasquale, Louis R., Singer, Michael S., Kalayoglu, Murat V.
• Primary Examiner(s): FAY, ZOHREH A
• Application Number:
  US14/504,788
• Publication Number:
  US 20150025151A1
• Time in Patent Office: 362 Days
• US Class Current: 1/1
• CPC Class Codes: A61K 31/5575 having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
• CPC Class Codes: A61K 8/37 Esters of carboxylic acids
• CPC Class Codes: A61K 8/42 Amides
• CPC Class Codes: A61K 8/69 containing fluorine
• CPC Class Codes: A61K 9/0014 Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/0021 Intradermal administration, e.g. through microneedle arrays, needleless injectors mechanical aspects A61M
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: A61K 9/0048 Eye, e.g. artificial tears
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61Q 19/06 for countering cellulitis

Abstract

The present invention relates to compositions, such as bimatoprost, latanoprost and travoprost, and methods to reduce fat in the body of an individual, for example, by topical administration, injection, and/or implantation of such compositions.

Claims

1. A method for reducing fat in a body of an individual, the method comprising administering to the skin of a portion of the body a composition comprising bimatoprost, represented by the formula:

2. The method of claim 1, wherein the individual has a cosmetic condition that comprises excess body fat.

3. The method of claim 1, wherein the individual has obesity.

4. The method of claim 1, wherein the excess deposit of body fat comprises obesity.

5. The method of claim 1, wherein the excess deposit of body fat is diffuse.

6. The method of claim 1, wherein the excess deposit of body fat is local.

7. The method of claim 1, wherein the excess deposit of body fat is on an area of the body selected from the group consisting of face, chin, neck, arms, chest, abdomen, buttocks, hips, thighs, and legs.

8. The method of claim 1, wherein the reducing occurs at a localized area selected from the group consisting of face, chin, neck, arms, chest, abdomen, buttocks, hips, thighs, and legs.

9. The method of claim 1, wherein the administering is to a localized area selected from the group consisting of face, chin, neck, arms, chest, abdomen, buttocks, hips, thighs, and legs.

10. The method of claim 1, wherein the route of administration is local.

11. The method of claim 1, wherein the composition is selected from the group consisting of a solution, a cream, an ointment, a gel, a lotion, a foam, a spray, a patch, and an implantable depot.

12. The method of claim 1, wherein the composition comprises a sustained-release formulation.

13. The method of claim 1, wherein the route of administration is selected from the group consisting of topical, subcutaneous, intradermal, subdermal, and transdermal.

14. The method of claim 13, wherein the route of administration is topical.

15. The method of claim 13, wherein the route of administration is subcutaneous.

16. The method of claim 13, wherein the route of administration is intradermal.

17. The method of claim 13, wherein the route of administration is subdermal.

18. The method of claim 13, wherein the route of administration is transdermal.

19. The method of claim 1, wherein the composition comprises bimatoprost.